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King Sau
osting by EAbstract Fluconazole-entrapped multilamellar liposomes were prepared using the thin-ﬁlm hydra-
tion method. The effects of cholesterol molar ratio, charge-inducing agents, and a-tocopherol ace-
tate on encapsulation efﬁciency values and in vitro drug release of multilamellar liposomes were
studied. Freeze-dried liposomal products were prepared with or without cryoprotectants. Results
showed that incorporation of stearylamine resulted in an increased entrapment of ﬂuconazole,
whereas incorporation of dicetyl phosphate decreased the drug entrapment efﬁciency. The incorpo-
ration of a-tocopherol acetate into ﬂuconazole multilamellar liposomes resulted in the increase of
entrapment efﬁciency of ﬂuconazole liposomes. In vitro release studies revealed that incorporation
of cholesterol into multilamellar liposomal formulations decreased drug permeability from formu-
lations. Positively charged ﬂuconazole multilamellar liposomes gave rise to a slow release rate com-
pared to neutral liposomes whereas negatively charged ﬂuconazole liposomes showed a rapid
release rate. Physical stability studies showed that lyophilized cake of liposomes without cryopro-
tectants was compact and difﬁcult to reconstitute compared to ﬂuffy easily reconstituted cakes upon
using cryoprotectants. Fluconazole retained in freeze-dried liposomes without cryoprotectants was
63.452% compared to 91.877% using three grams of trehalose as a cryoprotectant per gram lipid in
positively charged multilamellar liposomes. Physical stability studies showed superior potentials of
the lyophilized product after reconstitution in comparison with those of a solution product.
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lsevier1. Introduction
In recent years, increasing attention is being paid to the devel-
opment of controlled drug delivery system (CDDS). The
advantages of CDDS over conventional therapy are numerous,
including better plasma level proﬁle, increased patient compli-
ance, lower dosage and toxicity, possibility of targeting and
more efﬁcient utilization of active agent (Singla et al., 2000).
Liposomes are one of the most suitable drug delivery systems
to deliver the drug to the target organ and minimize the distri-
218 O.H. El-Nesr et al.bution of the drug to non-target tissues (Mezei, 1994; Fresta
et al., 1993). The extent of absorption of an ophthalmic drug
is limited by physiological factors such as reﬂex tearing and re-
ﬂex blinking that exist in the precorneal area, resulting in the
loss of an important drug (Lee, 1993). Liposomes can enhance
corneal drug absorption achieved through their ability to come
into intimate contact with the corneal and conjunctival sur-
faces. Earlier studies showed that liposome-associated idoxuri-
dine is superior to the solution form of the drug in the treatment
of Herpes simplex keratitis in rabbits (Dharma et al., 1986).
Fungal infections of the cornea, especially Candida, are
considered a major problem in ophthalmology because of
diagnostic and therapeutic difﬁculties (Narendran et al.,
2008). Candida was the most common cause of fungal endoph-
thalmitis. Fungal keratitis can impair vision or lead to total
blindness. So various speciﬁc antifungal agents have been used
(Klotz et al., 2000).
Fluconazole is a bis-triazole compound that exhibits a
broad spectrum of antifungal activity belonging to the group
of triazoles. It is effective against many fungal species includ-
ing Candida (Price et al., 1994). It acts as a fungiostatic agent.
The high penetration into the aqueous humor and low toxicity
of ﬂuconazole make it a good candidate for consideration as a
topical ocular antifungal agent (Abbasoglu et al., 2001). The
azole antifungal drugs inhibit the biosynthesis of ergosterol,
the major sterol found in the fungal cell membrane, which is
essential for the regulation of membrane ﬂuidity and integrity
and for fungal growth and proliferation (Ambrosini et al.,
1998). Although topical ﬂuconazole solutions in experimental
Candida keratitis have proved to be effective, with good pen-
etration into the cornea and aqueous humor, liposomal pene-
trations were still thought to provide potentially longer contact
time, allowing greater penetration of the ﬂuconazole (Behrens-
Baumann et al., 1990; Yee et al., 1997; Yilmaz and Maden,
2005). Previous studies on liposomal formulations of ﬂuconaz-
ole revealed that it was successful in eliminating experimental
Candida albicans infection of the rabbit cornea and it was supe-
rior over ﬂuconazole solution (Habib et al., 2009; Singh et al.,
1993).
In general, the proposed types of liposome dispersions pre-
pared from commercially available lipids do not meet the re-
quired standards for long-term stability of pharmaceutical
preparations if they are stored as aqueous dispersions. The
encapsulated drugs tend to leak out of the bilayer structure
and the liposomes might aggregate or fuse on storage and it
is generally necessary to use them within the ﬁrst few months
of preparation. As an alternative for storing aqueous liposo-
mal dispersions, freeze-dried liposomes are proposed (Assadul-
lahi et al., 1992; Madden and Boman, 1999).
Lyophilization increases the shelf-life of the ﬁnished prod-
uct by preserving it in a relatively more stable dry state espe-
cially if the drug is not stable in aqueous systems. Some
liposomal products in the market or in clinical trials are pro-
vided as a lyophilized powder (Sharma and Sharma, 1997).
The leakage problem is one of the limiting factors in the com-
mercial development of liposome products (Venuri et al.,
1991). A variety of sugars, including sucrose, glucose, fructose,
maltose, arabinose and trehalose, have been shown to act as
protectants during dehydration/rehydration of liposomes
(Crowe et al., 1985). Although other types of excipients have
also been reported to exert cryoprotective effects (Li et al.,
1992).In the present study, ﬂuconazole-entrapped multilamellar
liposomes were prepared using the thin-ﬁlm hydration method.
The effects of cholesterol molar ratio, a-tocopherol acetate and
charge-inducing agents on encapsulation efﬁciency values of
multilamellar liposomes were studied. Characterization of the
prepared multilamellar liposomes regarding particle size and
in vitro drug release was preformed. Physical stability of lipo-
somal formulations was done to investigate the stability of
ﬂuconazole liposomes at 4 and 25 C. Also freeze-drying of lip-
osomes was performed to study the effect of various cryopro-
tectants for their ability to protect liposomes against fusion
and leakage during lyophilization processes to increase the sta-
bility of the stored liposomes.
2. Materials and methods
2.1. Chemicals
Fluconazole was obtained from Medicorp (city, India) as a gift
sample. L-a-Phosphatidylcholine (PC), type X-E from dried
egg yolk, cholesterol (Chol), stearylamine (SA), dicetyl phos-
phate (DP), b-glucose, D-trehalose and b-lactose were pur-
chased from Sigma Chemical Co. (St. Louis, USA). a-
Tocopherol acetate was purchased from La Roche (France).
Chloroform, absolute ethyl alcohol, potassium dihydrogen
phosphate and disodium hydrogen phosphate were purchased
from El-Nasr Pharmaceutical Co. (Egypt). Diethyl ether was
purchased from Merck (Germany). Spectra/Por dialysis mem-
brane, 12,000–14,000 molecular weight cut off was purchased
from Spectrum Laboratories Inc. (USA). All chemicals and
solvents were of analytical grade.
2.2. Methods
2.2.1. Preparation of ﬂuconazole multilamellar liposomes by
thin-ﬁlm hydration method
Fluconazole multilamellar liposomal formulations with differ-
ent molar ratios were prepared using the thin-ﬁlm hydration
technique. The lipid components 200 mg [egg phosphatidyl-
choline and cholesterol either alone or mixed with charge-
inducing agent and a-tocopherol acetate] with different molar
ratios were dissolved in chloroform:methanol mixture [2:1, v/v]
in a round-bottomed ﬂask. Then 30 mg ﬂuconazole, dissolved
in 3 ml of the same solvent mixture, was added to the lipid
solution. The organic solvents were slowly removed under re-
duced pressure, using a rotary evaporator, at 40 C such that a
very thin ﬁlm of dry lipids was formed on the inner surface of
the ﬂask. The dry lipid ﬁlm was slowly hydrated with 10 ml of
phosphate buffered saline [pH 7.4]. The resulting suspension
was mechanically shaken for 1 h at room temperature using
mechanical shaker leading to the formation of multilamellar
liposomes. The liposomal dispersion was left to mature over
night at 4 C to ensure full lipid hydration. All the above-men-
tioned steps were performed under aseptic conditions. All
glasswares were sterilized by autoclaving. Phosphate buffered
saline was passed through a 0.22 lm membrane ﬁlter, and
the entire procedure was performed in a laminar ﬂow hood
(Esco. Singapore). Fluconazole liposomes were separated from
unentrapped drug by centrifugation at 13,000 rpm for 1 h and
at [2 C] using cooling ultracentrifuge. The cake, thus
formed, was washed twice each with 10 ml phosphate buffered
saline and recentrifuged again for 1 h.
Table 1 The effect of cholesterol molar ratio and charge
inducers on the encapsulation efﬁciency of ﬂuconazole into
multilamellar liposomes.
Liposome composition
(molar ratio)
Charge Encapsulation
eﬃciency
(% ±S.D.)
Phosphatidylcholine Neutral 23.104 ± 0.197
Phosphatidylcholine:
cholesterol (1:0.6)
Neutral 44.675 ± 0.324
Phosphatidylcholine:cholesterol:
stearylamine (1:0.6:0.1)
Positive 52.657 ± 0.231
Phosphatidylcholine:cholesterol:
dicetyl phosphate (1:0.6:0.1)
Negative 38.877 ± 0.164
Phosphatidylcholine:cholesterol (1:0.8) Neutral 50.236 ± 0.335
Phosphatidylcholine:cholesterol:
stearylamine (1:0.8:0.1)
Positive 59.998 ± 0.194
Phosphatidylcholine:cholesterol:
dicetyl phosphate(1:0.8:0.1)
Negative 43.533 ± 0.244
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liposomes
The entrapped drug concentrations were determined after the
lysis of prepared liposomes with absolute alcohol and sonica-
tion for 10 min (Law and Shih, 2001). The concentration of
ﬂuconazole in absolute alcohol was determined spectrophoto-
metrically at 261 nm. The entrapment efﬁciency expressed as
entrapment percentage was calculated through the following
relationship (Gulati et al., 1998).
Entrapment Efficiency Percentage¼ Entrapped drug=Total drug 100:
Different factors inﬂuencing the encapsulation of ﬂuconaz-
ole into multilamellar liposomes prepared by thin-ﬁlm hydra-
tion method such as (cholesterol molar ratio, effect of charge
and effect of a-tocopherol acetate) were studied to ﬁnd out
the conditions for optimal drug entrapment.
2.2.3. Particle size analysis
The mean particle size of the liposomes was determined by
light scattering based on laser diffraction using the laser dif-
fraction particle size analyzer [Malvern Master Sizer, Malvern
Instruments Limited, Worcestershire, UK].
2.2.4. In vitro release of ﬂuconazole from multilamellar
liposomes
The release of ﬂuconazole from all multilamellar liposomal
formulations with different compositions was determined
using the membrane diffusion technique. In brief, an accu-
rately measured amount of ﬂuconazole solution or ﬂuconazole
liposomal formulations, equivalent to 20 mg ﬂuconazole, was
suspended in 1 ml of phosphate buffered saline [pH 7.4] in a
glass cylinder having a length of 20 cm and a diameter of
2.5 cm. This cylinder was ﬁtted, before addition of liposomal
suspension, with a presoaked membrane [Spectra/Por mem-
brane] and was placed in a beaker (100 ml) containing 35 ml
phosphate buffered saline [pH 7.4]. The whole set was placed
on a magnetic stirrer adjusted to a constant speed [150 rpm].
Samples were collected every 1 h over a period of 10 h and as-
sayed spectrophotometrically for drug content at 261 nm. The
results were the mean values of three runs. The obtained re-
sults were subjected to kinetic treatment to determine the order
of release pattern and release rate constant.
2.2.5. Stability study of liposomal formulations
Physical stability study of ﬂuconazole liposomes was carried
out to determine the comparative leakage of the drug from lip-
osomes stored at different conditions compared to each other.
After washing and removal of the free drug, each liposomal
formulation was stored either at 4 C or at 25 C. At predeter-
mined time intervals of 15, 30, 60 and 90 days (Vemuri and
Rhodes, 1995). The entrapment efﬁciency of ﬂuconazole lipo-
somes were determined using stability indicating HPLC meth-
od (Xu and Lawrence, 1999). In brief, the stationary phase was
at hypersil C18 (4.6 mm · 25 cm), the mobile phase was a mix-
ture of 450 ml methanol and 550 ml 0.025 M sodium phos-
phate buffer with pH adjusted to 7 with phosphoric acid and
was delivered at a ﬂow rate of 1 ml/min. An aliquot of the
stored samples of each formulation was diluted with phosphate
buffered saline and centrifuged in a cooling ultracentrifuge at
13,000 rpm for 1 h to separate the free drug that leaked out
of liposomes during the storage period. One hundred microli-ters of liposomal suspension were completely lysed by 0.1%
(w/v) triton X-100 then transferred to 50 ml volumetric ﬂask
and the volume was completed with the mobile phase ﬁltered
through microﬁlter. Standard ﬂuconazole solution were pre-
pared by diluting speciﬁc volume of the stock standard concen-
tration of (3 mg/ml) to get several concentrations (0.05, 0.075,
0.1, 0.125.0.15, and 0175 mg/ml). Fluconazole was detected at
wave length 261 nm; the injection volume was 20 ll under
these conditions; the retention time for ﬂuconazole was
6.1 min.
2.2.6. Freeze-drying and physical stability of liposomal
formulations
The cryoprotectant (glucose, lactose or trehalose) was dis-
solved in phosphate buffered saline at different concentrations
of 1, 2, 3 and 4 g/g dry phospholipids. Liposomal suspensions
in buffer alone, or after mixing with equal volume of each
cryoprotectant buffered solution, were freeze-dried where the
liquid was frozen to 30 C and then freeze-dried for 24 h un-
der vacuum at 10 C. The resulting lyophilization cakes were
rehydrated to its original volume at room temperature with
phosphate buffered saline [pH 7.4] and subjected to the follow-
ing investigations.
2.2.7. Measurement of drug leakage after freeze-drying
After reconstitution, an aliquot of each formulation was cen-
trifuged in an ultracentrifuge at 13,000 rpm for 1 h at
[2 C] to separate the free drug which leaked out of liposomes
in the supernatant during freeze-drying. The amount of drug in
the supernatant was measured by using HPLC method.
2.2.8. Particle size analysis
The vesicle size range and mean diameter of the liposomes
were determined after freeze-drying-rehydration cycle using
the laser diffraction particle size analyzer.
3. Results and discussion
3.1. Drug entrapment efﬁciency
By inspection of Table 1, it is obvious that ﬂuconazole encap-
sulation efﬁciency varied with the lipid composition and the
Table 3 Particle size distribution of ﬂuconazole multilamellar
liposomes (phosphatidylcholine:cholesterol 1:0.8 M ratio) of
different charges.
Cumulative
distribution
percentile
Particle volume (lm) of liposomal formulations
Neutrala Negatively-chargedb Positively-chargedc
10.0% 2.62 1.48 4.49
20.0% 3.36 2.63 5.92
50.0% 4.93 4.11 8.73
80.0% 6.69 5.86 10.78
90.0% 7.38 5.24 11.35
Distribution
modal
sizes (lm)
7.20 6.00 10.79
a Phosphatidylcholine:cholesterol:a-tocopherol acetate (1:0.8:0.1)
molar ratio.
b Phosphatidylcholine:cholesterol:dicetyl phosphate:a-tocopherol
acetate (1:0.8:0.1:0.1) molar ratio.
c Phosphatidylcholine:cholesterol:stearylamine:a-tocopherol ace-
tate (1:0.8:0.1:0.1) molar ratio.
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cerning the effect of cholesterol content on encapsulation efﬁ-
ciency, results showed that the percentage entrapment
efﬁciency of ﬂuconazole increased by increasing the cholesterol
content. The percentage entrapment efﬁciency of ﬂuconazole
in multilamellar liposomes composed of egg phosphatidylcho-
line alone was 23.104%, whereas the percentage was increased
to 44.675% in liposomes prepared with phosphatidylcho-
line:cholesterol in the ratio 1:0.6. Further increase in the
entrapment efﬁciency to 50.236% was recorded for liposomes
composed of phosphatidylcholine:cholesterol in the ratio 1:0.8.
The one-way analysis of variance ANOVA showed a signiﬁ-
cant difference between the different concentrations of choles-
terol used in the preparation of multilamellar liposomal
formulations at P< 0.05. This increase in entrapment efﬁ-
ciency is explained by the fact that by increasing the choles-
terol concentration in the lipidic bilayer, the rigidity of the
latter increases steadily, resulting in a higher stability and re-
duced permeability of the liposomal membrane (Du Plessis
et al., 1996), and hence greater drug retention (Perugini and
Pavanetto, 1998).
Concerning the effect of charge-inducing agents on the
encapsulation efﬁciency of ﬂuconazole in the prepared multila-
mellar liposomes, the results showed that positively charged
liposomes exhibited the highest encapsulation efﬁciency, fol-
lowed by neutral ones and then the negatively charged lipo-
somes using the same phosphatidylcholine:cholesterol molar
ratio. The higher ﬂuconazole encapsulation efﬁciency of posi-
tively charged liposomes compared to that of the negatively
charged liposomes may be due to the electrostatic attraction
force that occurred between the partial negative centers, avail-
able in the molecules of the drug and stearylamine. This attrac-
tion would account for the higher encapsulation efﬁciency
values when compared to those of the negatively charged lipo-
somes, where such electrostatic attraction would not occur
(Law and Hung, 1998).
The effect of incorporation of a-tocopherol acetate (vita-
min-E) on the encapsulation efﬁciency of ﬂuconazole into mul-
tilamellar liposomes prepared by thin-ﬁlm hydration method
was investigated. Table 2 shows the result of the effect of incor-
poration of a-tocopherol acetate (vitamin-E) on encapsulation
efﬁciency of ﬂuconazole into multilamellar vesicles liposomes
prepared by thin-ﬁlm hydration method. Results showed that
the percentage encapsulation efﬁciencies of ﬂuconazole were
increased, after the incorporation of a-tocopherol acetate
(vitamin-E) into liposomes from 44.675% in the molar ratio
1:0.6 in neutral liposomes composed of (egg phosphatidyl-
choline:cholesterol) to 47.235% in the molar ratio 1:0.6:0.1
composed of (phosphatidylcholine:cholesterol:a-tocopherol
acetate), from 52.657% to 56.341% in positively charged lipo-
somes and from 38.877% to 41.998% in negatively charged
liposomes of the same molar ratio. Student t-test shows thatTable 2 The effect of incorporation of a-tocopherol acetate (vitami
liposomes.
Liposome composition (molar ratio)
Phosphatidylcholine:cholesterol:a-tocopherol acetate (1:0.6:0.1)
Phosphatidylcholine:cholesterol:stearylamine:a-tocopherol acetate (1:0.6:
Phosphatidylcholine:cholesterol:dicetyl phosphate:a-tocopherol acetate (1there is a signiﬁcant difference between liposomal formulations
of the same molar ratio after and before incorporation of a-
tocopherol acetate at a= 0.05. The increase in the entrapment
efﬁciency is explained by the fact that incorporation of a-
tocopherol acetate into liposomal preparations improves the
membrane rigidity and makes it more hydrophobic and less
permeable (Clares et al., 2009). Moreover a reduction in the li-
pid peroxidation and decrease in the formation of lysophos-
pholipid occur when tocopherol is added.
3.2. Particle size analysis
The results of particle size measurements for freshly prepared
neutral, positively charged and negatively charged multilamel-
lar liposomal dispersions with lipid component and a-tocoph-
erol acetate in the molar ratio 1:0.8 are presented in Table 3.
The particle size distribution of the tested liposomal formula-
tions showed unimodal normal symmetrical frequency distri-
bution patterns. The mean particle diameter of neutral
multilamellar vesicles was found to be around 7.20 lm. The
mean particle diameter of negatively charged vesicles was
found to be 6.00 lm and positively charged was around
10.79 lm. These results can be attributed to the inclusion of
a charge inducer in liposomes, which increased the spacing be-
tween the adjacent bilayers, resulting in the formation of lipo-
somes larger in size compared with the neutral ones
(Nagarsenker et al., 2002). This increase in particle size would
account, as mentioned previously, for the higher encapsulationn-E) on encapsulation efﬁciency of ﬂuconazole into multilamellar
Charge Encapsulation eﬃciency (% ±S.D.)
Neutral 47.235 ± 0.223
0.1:0.1) Positive 56.341 ± 0.255
:0.6:0.1:0.1) Negative 41.998 ± 0.316
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neutral.
3.3. In vitro release studies
Release proﬁles of ﬂuconazole from neutral, negatively
charged and positively charged multilamellar liposomes pre-
pared by thin-ﬁlm hydration method and composed of phos-
phatidylcholine:cholesterol:a-tocopherol acetate (1:0.6:0.1)
and (1:0.8:0.1) molar ratios are shown in Figs. 1 and 2, respec-
tively. From the release proﬁles, it is obvious that the increase
of cholesterol molar ratio in the prepared liposomal formula-
tions progressively decreased the release of ﬂuconazole from
the vesicles. The percentage of drug released from the liposo-
mal formulations after 10 h of the experiment from neutral lip-
osomes (1:0.6:0.1) reached about 56.885%. For positively
charged (1:0.6:0.1:0.1) liposomes, the release rate was slower
than that of neutral liposomes and the percentage of drug re-
leased after 10 h was 51.847%. In contrast, negatively charged0
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Figure 1 In vitro release of ﬂuconazole from multilamellar
liposomes composed of Phosphatidylcholine:cholesterol:a-tocoph-
erol acetate (1:0.6:0.1) in phosphate buffered saline.
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Figure 2 In vitro release of ﬂuconazole from multilamellar
liposomes composed of phosphatidylcholine:cholesterol:a-tocoph-
erol acetate (1:0.8:0.1) in phosphate buffered saline.liposomes showed a rapid release rate where the amount of
drug released after 10 h was 62.441% for the same molar ratio.
Fig. 2 shows the release proﬁle of ﬂuconazole from neutral,
positively charged and negatively charged multilamellar lipo-
somal formulations composed of phosphatidylcholine:choles-
terol of 1:0.8 M ratios in phosphate buffered saline. The
results showed that increasing the molar ratio to cholesterol
80% decreased the release rate of the drug from liposomes.
Positively charged liposomes had the slowest release rate and
the highest encapsulation efﬁciency, relative to neutral and
negatively charged liposomes. The signiﬁcance of difference
between the dissolution of different studied formulations was
evaluated using one-way analysis of variance ANOVA fol-
lowed by Dunnett Multiple comparison test. The differences
were considered signiﬁcant at P< 0.01. The order of release
and encapsulation characteristics of ﬂuconazole-containing
liposomes may be due to the electrostatic attraction involved
between the drug and the positively charged liposomes.
Table 4 shows linear regression analysis for the release data
of neutral, positively charged and negatively charged lipo-
somes. It reveals that the drug was released from liposomes
by a diffusion-controlled mechanism and a linear correlation
occurs when the percent of drug released was plotted against
the square root of time according to Higuchi equation. These
results are in agreement with many researchers who found that
the drugs were released from liposomes by a diffusion-con-
trolled mechanism (Vemuri and Rhodes, 1995).
3.4. Physical stability studies
Physical stability study of ﬂuconazole liposomes was conducted
at refrigeration temperature [4 C] and at room temperature
[25 ± 2 C] for a period of 3 months. Drug leakage from the
liposomes was evaluated at deﬁnite time intervals (Patel and
Misra, 1999). The results are demonstrated in Table 5 in terms
of percentage ﬂuconazole retained in the liposomes. Fluconaz-
ole liposomal formulations investigated were: neutral (phos-
phatidylcholine:cholesterol:a-tocopherol acetate; 1:0.8:0.1 M
ratio), positively charged (phosphatidylcholine:cholesterol:a-
tocopherol acetate:stearylamine 1:0.8:0.1:0.1 M ratio) and
negatively charged (phosphatidylcholine:cholesterol:a-tocoph-
erol acetate:dicetyl phosphate; 1:0.8:0.1:0.1 M ratio) liposomes
prepared by the thin-ﬁlm hydration method. The percent ﬂuco-
nazole retained in liposomal formulations after 90 days were
88.853%, 87.721% and 86.439% for positively charged,
negatively charged and neutral multilamellar liposomes,
respectively. Positively charged liposomes showed better stabil-
ity, as indicated by higher drug retention followed by the neg-
atively charged liposomes then, the neutral liposomes.
After 90 days storage at 25 C, the retained drug was
84.548%, 81.698% and 72.785% for positively charged, nega-
tively charged and neutral multilamellar liposomes, respec-
tively. One-way ANOVA revealed that differences are
signiﬁcant at P< 0.05 between different formulations at
refrigeration temperature [4 C] and at room temperature
[25 ± 2 C].
These results can be explained by the fact that charge on
lipids is an important parameter inﬂuencing liposomal behav-
ior. In this way, high surface potential might contribute to
liposome physical stability by reducing the rate of aggregation
and fusion of liposomes during storage (Armengol and Estel-
rich, 1995). The visual appearance observations revealed that
Table 4 Diffusional order of release of ﬂuconazole from different liposomal formulations using the correlation coefﬁcient parameter.
Liposomal formulation composition (molar ratio) Liposomal
formulation
charge
Kinetic analysis using correlation
coeﬃcient (r) according to
Zero
order
First
order
Diﬀusion
Phosphatidylcholine:cholesterol:a-tocopherol acetate (1:0.6:0.1) Neutral 0.9789 0.9925 0.9981
Phosphatidylcholine:cholesterol:stearylamine:a-tocopherol acetate (1:0.6:0.1:0.1) Positive 0.9795 0.9949 0.9989
Phosphatidylcholine:cholesterol:dicetyl phosphate:a-tocopherol acetate (1:0.6:0.1:0.1) Negative 0.9936 0.9962 0.9978
Phosphatidylcholine:cholesterol:a-tocopherol acetate (1:0.8:0.1) Neutral 0.9783 0.9904 0.9943
Phosphatidylcholine:cholesterol:stearylamine:a-tocopherol acetate (1:0.8:0.1:0.1) Positive 0.9895 0.9949 0.9952
Phosphatidylcholine:cholesterol:dicetyl phosphate:a-tocopherol acetate (1:0.8:0.1:0.1) Negative 0.9815 0.9928 0.9933
Table 5 Stability of multilamellar ﬂuconazole liposomes (1:0.8) molar ratio of different charges stored at 4 C and 25 C.
Time (days) Fluconazole retained in multilamellar liposomes (% ±S.D.)
Stored at 25 C Stored at 4 C
Neutrala Negatively-chargedb Positively-chargedc Neutrala Negatively-chargedb Positively-chargedc
Zero 100 ± 000 100 ± 000 100 ± 000 100 ± 000 100 ± 000 100 ± 000
15 85.439 ± 0.314 89.453 ± 0.521 92.652 ± 0.313 89.556 ± 0.244 93.386 ± 0.175 95.742 ± 0.426
30 79.986 ± 0.436 86.639 ± 0.421 89.864 ± 0.362 87.653 ± 0.177 92.476 ± 0.355 94.833 ± 0.217
60 73.974 ± 0.328 83.748 ± 0.352 88.649 ± 0.279 87.843 ± 0.466 88.638 ± 0.351 91.438 ± 0.531
90 72.785 ± 0.364 81.698 ± 0.522 84.548 ± 0.467 86.439 ± 0.288 87.721 ± 0.411 88.853 ± 0.253
a Phosphatidylcholine:cholesterol:a-tocopherol acetate (1:0.8:0.1) molar ratio.
b Phosphatidylcholine:cholesterol:dicetyl phosphate:a-tocopherol acetate (1:0.8:0.1:0.1) molar ratio.
c Phosphatidylcholine:cholesterol:stearylamine:a-tocopherol acetate (1:0.8:0.1:0.1) molar ratio.
222 O.H. El-Nesr et al.the aqueous liposomal formulations stored at 4 C showed no
signs of separation or change in color up to 6 months. On the
other hand, the liposomal formulations stored at room temper-
ature showed slight separation and yellow discoloration after
90 days. These results were in agreement with what has been
previously recommended that liposomal suspensions should
be kept refrigerated to achieve the best stability.
3.5. Freeze-drying of ﬂuconazole liposomes
Freeze-drying increases the shelf-life of liposomal formulations
and preserves it in dried form as a lyophilized cake to be recon-
stituted with water for injection prior to administration. To
maintain the same particle size distribution after freeze-dry-
ing-rehydration cycle, a cryoprotectant needs to be added.
Various sugars were investigated for their ability to protect lip-
osomes against fusion and leakage during lyophilization pro-
cesses (Venuri et al., 1991). This protective ability can extend
to both prevention of vesicle fusion and retention of encapsu-
lated compound within the liposome (Madden and Boman,
1999).
Table 6 shows percent ﬂuconazole retained in freeze-dried
multilamellar liposomes, respectively, as a function of cryopro-
tectants/lipid mass ratio. It is clear that only 63.452% ﬂuco-
nazole is retained for positively charged multilamellar
liposomes in the absence of cryoprotectants. The leakage of
entrapped ﬂuconazole is explained by the fact that in the ab-
sence of any protective agents; lyophilization and rehydration
of a liposomal suspension can result in fusion and leakage of
internal aqueous contents. The percentage of ﬂuconazoleretained in liposomes increased using increasing amounts of
glucose for freeze-dried positively charged multilamellar lipo-
somes. Whereas using lactose as a cryoprotectant, the amounts
of ﬂuconazole retained in liposomes were 72.735%, 81.821%,
86.249% and 89.952% for positively charged multilamellar
liposomal formulations freeze-dried with 1, 2, 3 and 4 g lac-
tose/g lipid, respectively. ANOVA test showed a signiﬁcant
difference between all parts at P< 0.05. Trehalose was found
to be more effective than other sugars at lower concentration
where, the amounts of ﬂuconazole retained in liposomes were
found to be 78.654%, 90.634%, 91.877% and 92.855% for
positively charged multilamellar liposomes freeze-dried with
1, 2, 3 and 4 g trehalose/g lipid, respectively. ANOVA followed
by Dunnett Multiple comparison test showed a signiﬁcant dif-
ference between all parts at P< 0.05 except between the posi-
tive liposomes and the concentration of trehalose above 3 g. It
is obvious that all the three sugars used, either monosaccharide
(glucose) or disaccharide (lactose or trehalose), stabilized the
vesicles in the freeze-dried state and protected the liposomes
against fusion and leakage. However, lactose and glucose
can achieve nearly similar protection. Also, with increasing
concentrations of added cryoprotectants, retention of ﬂuco-
nazole during lyophilization increases steadily up to 3 g treha-
lose/g lipid. Previous studies also demonstrated the superiority
of trehalose compared to other sugars in preventing the fusion
and leakage of entrapped drug where trehalose has the ability
to preserve biological membranes in the absence of water. It
has been suggested that the presence of trehalose during the
drying process preserves the structure of drug-loaded lipo-
somes in the anhydrous state by replacing the water molecules
Table 6 Retention of ﬂuconazole in freeze-dried multilamellar liposomes as a function of cryoprotectants/lipid mass ratio.
g Cryoprotectant/g lipid Fluconazole retained in liposomal formulations (% ±S.D.)
Neutrala Negatively-chargedb Positively-chargedc
None 61.544 ± 0.212 62.221 ± 0.456 63.452 ± 0.218
1 g glucose/g lipid 64.254 ± 0.423 65.877 ± 0.327 66.454 ± 0.447
2 g glucose/g lipid 67.329 ± 0.531 68.965 ± 0.463 69.789 ± 0.376
3 g glucose/g lipid 81.705 ± 0.638 82.543 ± 0.237 82.844 ± 0.374
4 g glucose/g lipid 81.644 ± 0.538 82.237 ± 0.448 83.994 ± 0.472
1 g lactose/g lipid 70.784 ± 0.365 71.662 ± 0.463 72.735 ± 0.518
2 g lactose/g lipid 83.133 ± 0.432 83.244 ± 0.165 81.821 ± 0.341
3 g lactose/g lipid 85.174 ± 0.136 85.867 ± 0.581 86.249 ± 0.361
4 g lactose/g lipid 88.328 ± 0.462 88.655 ± 0.418 89.952 ± 0.419
1 g trehalose/g lipid 77.167 ± 0.376 77.871 ± 0.365 78.654 ± 0.356
2 g trehalose/g lipid 86.932 ± 0.368 87.429 ± 0.384 90.634 ± 0.163
3 g trehalose/g lipid 89.622 ± 0.451 90.633 ± 0.473 91.877 ± 0.278
4 g trehalose/g lipid 91.659 ± 0.428 92.741 ± 0.276 92.855 ± 0.481
a Phosphatidylcholine:cholesterol:a-tocopherol (1:0.8:0.1) molar ratio.
b Phosphatidylcholine:cholesterol:dicetyl phosphate:a-tocopherol (1:0.8:0.1:0.1) molar ratio.
c Phosphatidylcholine:cholesterol:stearylamine:a-tocopherol (1:0.8:0.1:0.1) molar ratio.
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almost 100% of the entrapped solute was retained in hydrated
vesicles previously freeze-dried with trehalose (Sun et al.,
1996).
Fusion or aggregation of liposomes during freeze-drying
process can be monitored by measuring the mean particle
diameter of liposomes after freeze-drying-rehydration cycle
and compared with the results of freshly prepared liposomes
of the same molar ratio. Results revealed that addition of cry-
oprotectants during freeze-drying of liposomes prevents aggre-
gation of liposomes and maintains the same particle size
distribution after freeze-drying-rehydration cycle. Mean parti-
cle diameters were found to be 7.44, 6.54 and 10.78 lm for
neutral, negatively charged and positively charged multilamel-
lar liposomes, respectively, freeze-dried with trehalose and
rehydrated with water. These results are very close to those
of freshly prepared liposomes where the mean particle diame-
ters were found to be 7.20, 6.00 and 10.79 lm for freshly pre-
pared neutral, negatively charged and positively charged
multilamellar liposomes, respectively. Such results conﬁrm
the previously mentioned effects of cryoprotectants in main-
taining the same particle distribution.4. Conclusions
Fluconazole multilamellar liposomal formulations were pre-
pared using the thin-ﬁlm hydration method. Incorporation of
cholesterol into ﬂuconazole-entrapped multilamellar lipo-
somes increased the rigidity or microviscosity of the bilayer,
and lowered the permeability of ﬂuconazole from liposomes
resulting in greater drug retention. Incorporation of stearyl-
amine resulted in an increased entrapment of ﬂuconazole,
whereas incorporation of dicetyl phosphate decreased the
entrapment efﬁciency of ﬂuconazole into liposomes. Incorpo-
ration of a-tocopherol acetate (vitamin-E) into ﬂuconazole
multilamellar liposomes resulted in the increase of entrapment
efﬁciency of ﬂuconazole liposomes. Positively charged ﬂuco-
nazole multilamellar liposomes gave rise to a slow release rate
than neutral liposomes of the same molar ratios, whereas neg-
atively charged ﬂuconazole-entrapped multilamellar liposomesshowed a faster release rate. Physico-chemical stability studies
showed superior potentials of the lyophilized product after
reconstitution in comparison with those of the solution prod-
uct. We could conclude that all tested sugars have cryoprotec-
tant effect that stabilized liposomes in the freeze-dried state,
where trehalose offered the most superior cryoprotectant effect
for freeze-dried ﬂuconazole liposomes.
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